Impact of sildenafil therapy on pulmonary arterial hypertension in adults with congenital heart disease

Cardiovascular Therapeutics
Xian-Ling LuJian-Guo He

Abstract

It has been demonstrated that sildenafil is effective in patients with pulmonary arterial hypertension (PAH). However, the impact of sildenafil on PAH in adults with congenital heart disease (CHD) has been less investigated. In this prospective, open-label, uncontrolled and multicenter study, 60 patients with PAH related to CHD received oral sildenafil (75 mg/day) for 12 weeks. The enrolled patients underwent six-minute walk test (SMWT) and cardiac catheterization at the beginning and the end of the 12 weeks. The primary end point was the changes in exercise capacity assessed by SMWT; the secondary end point included assessment of functional class, evaluation of cardiopulmonary hemodynamics, and clinical worsening (defined as death, transplantation, and rehospitalization for PAH). Drug safety and tolerability were also examined. Oral sidenafil significantly increased SMWT distances (422.94 ± 76.95 m vs. 371.99 ± 78.73 m, P < 0.0001). There was also remarkable improvement in Borg dyspnea score (2.1 ± 1.32 vs. 2.57 ± 1.42, P = 0.0307). Moreover, significant improvements in World Healthy Organization (WHO) functional class and cardiopulmonary hemodynamics were also discovered (mean pulmonary artery pressure, P = 0.0002; cardiac in...Continue Reading

References

Sep 25, 1999·The American Journal of Cardiology·W J CantorS C Siu
Mar 22, 2002·The New England Journal of Medicine·Lewis J RubinGerald Simonneau
Jun 27, 2002·Journal of the American College of Cardiology·Julien I E Hoffman, Samuel Kaplan
Jul 2, 2002·American Journal of Respiratory and Critical Care Medicine·UNKNOWN ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories
Oct 2, 2002·Lancet·Hossein Ardeschir GhofraniFriedrich Grimminger
Nov 26, 2002·American Journal of Respiratory and Critical Care Medicine·Karl P KuhnIvan M Robbins
Feb 22, 2005·International Journal of Cardiology·Anand ChockalingamSmrita Dorairajan
Nov 18, 2005·The New England Journal of Medicine·Nazzareno GalièUNKNOWN Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group
Oct 10, 2006·International Journal of Cardiology·Zek S LimGruschen R Veldtman
Feb 28, 2007·Circulation·Gerhard-Paul Diller, Michael A Gatzoulis
Feb 28, 2009·Journal of the American College of Cardiology·Maurice Beghetti, Nazzareno Galiè

❮ Previous
Next ❯

Citations

Nov 28, 2013·Heart Failure Clinics·Alexander R OpotowskyMaurice Beghetti
Sep 20, 2015·American Heart Journal·Kishan S ParikhZainab Samad
Apr 5, 2013·Journal of Clinical Pharmacology·Yun-Juan SunJian-Guo He
Jun 17, 2011·Clinical Cardiology·Wei-Jie ZengUNKNOWN Sildenafil Therapy on Pulmonary Arterial Hypertension Associated With Different Types of Congenital Heart Disease Study Grou
Oct 1, 2011·Journal of Clinical Pharmacology·Wei-Jie ZengJian-Guo He
Jan 5, 2011·International Journal of Clinical Practice. Supplement·L SavaleO Sitbon
Jul 31, 2013·Expert Review of Cardiovascular Therapy·Robert M RadkeHelmut Baumgartner
Jan 1, 2014·Global Cardiology Science & Practice·Ghazwan Butrous
Aug 14, 2019·Heart Failure Reviews·Michail PapamichalisFilippos Triposkiadis
Jun 10, 2011·Current Opinion in Cardiology

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.